Capricor Therapeutics, Inc. key statistics and ratios

In fiscal 2025, Capricor Therapeutics, Inc. had return on equity of -46.6%, debt equal to 0.0% of equity and a current ratio of 9.01. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Capricor Therapeutics, Inc.: financial ratios, annual
Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Operating margin	−361.7%	<−999%	<−999%	−125.7%	−228.6%	−424.6%	−482.4%	−917.0%	−769.5%	<−999%	<−999%	<−999%	−95.6%	−191.1%	—
Net margin	−84.9%	<−999%	<−999%	−129.9%	−233.0%	−470.3%	91.2%	−908.9%	−760.4%	<−999%	<−999%	<−999%	−88.5%	−181.7%	—
Free-cash-flow margin	−343.4%	<−999%	<−999%	16.6%	−198.4%	−366.3%	−534.9%	−848.3%	−678.7%	<−999%	<−999%	114.3%	−106.9%	−184.8%	—
Return on equity	−69.4%	−63.2%	—	—	—	—	67.3%	−191.8%	−133.4%	−78.0%	−67.2%	−134.5%	−129.6%	−48.2%	−46.6%
Return on assets	−83.8%	−61.0%	−162.2%	−64.9%	−86.6%	−108.0%	13.9%	−119.0%	−75.1%	−59.7%	−52.7%	−63.5%	−41.0%	−35.3%	−39.9%
Asset turnover	0.99	0.06	0.09	0.50	0.37	0.23	0.15	0.13	0.10	0.01	0.01	0.06	0.46	0.19	—
Current ratio	2.42	9.81	1.79	1.84	2.14	3.70	9.40	6.75	11.74	11.33	8.82	1.82	1.63	7.77	9.01
Debt to equity	0.0%	0.0%	—	—	—	—	0.0%	0.0%	0.0%	1.1%	10.8%	28.6%	14.9%	2.3%	0.0%
Interest cover (operating income ÷ interest)	—	—	n/m	n/m	n/m	n/m	n/m	—	—	—	—	—	—	—	n/m
R&D as % of revenue	305.4%	>999%	>999%	162.7%	249.3%	401.2%	403.8%	722.0%	511.6%	>999%	>999%	855.1%	144.8%	224.4%	—
Capital spending as % of revenue	0.1%	6.9%	11.2%	3.4%	2.4%	4.8%	1.2%	18.9%	0.0%	176.5%	488.5%	78.4%	5.2%	5.2%	—
Free cash flow ÷ net income	—	—	—	—	—	—	−586.6%	—	—	—	—	—	—	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Capricor Therapeutics, Inc.: financial ratios, quarterly
Quarter	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023	2024 Q1Mar 2024	2024 Q2Jun 2024	2024 Q3Sept 2024	2024 Q4Dec 2024
Operating margin	−274.0%	−197.8%	−111.0%	−10.6%	−209.2%	−291.9%	−575.2%	−69.1%
Net margin	−260.1%	−188.0%	−103.3%	−6.3%	−199.6%	−277.0%	−555.2%	−63.9%
Free-cash-flow margin	129.3%	−243.9%	−146.5%	−100.5%	−38.3%	−310.9%	−515.2%	−137.3%
Current ratio	1.25	1.11	0.90	1.63	1.57	1.37	4.19	7.77
R&D as % of revenue	256.5%	225.1%	162.1%	82.2%	226.2%	314.9%	522.1%	130.8%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

8 /100

Weak moat

How hard Capricor Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Net income has been a median -48.7% of total assets over 10 years.
Durability 10 / 20

Operating margin has been a median -407.5%; its worst year was -6190.2%.
Cash conversion 0 / 20

Free cash flow was positive in 0 of 10 years, at a median -419.5% of revenue.
Discipline 0 / 20

The diluted share count rose 598.6% over five years; stock-based pay has been a median 50.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CAPR vs JANX CAPR vs CRSP ABEO vs CAPR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Capricor Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Capricor Therapeutics, Inc.